Cardiovascular Drugs Practice Questions

Q: Which of the following GLP-1 analogues is cardioprotective?

Liraglutide. ***Liraglutide***- **Liraglutide** (Victoza) [1], [2] has demonstrated significant **cardiovascular benefits** in patients with type 2 diabetes and established cardiovascular disease, specifically reducing the risk of major adverse cardiovascular events (MACE) in clinical trials such as the LEADER trial.- This benefit is thought to be mediated through various mechanisms, including improvements in **blood pressure**, **lipid profile**, and direct effects on **vascular function**.*Exenatide*- While **exenatide** (Byetta, Bydureon) is a GLP-1 receptor agonist [1], [2], it has not shown the same degree of robust cardiovascular protective effects as liraglutide in clinical outcome trials.- Studies like EXSCEL demonstrated **non-inferiority** for cardiovascular outcomes but not superiority or a significant reduction in MACE like liraglutide.*Lixisenatide*- **Lixisenatide** (Adlyxin) is another short-acting GLP-1 receptor agonist. The ELIXA trial, which evaluated its cardiovascular safety, showed **non-inferiority** but did not demonstrate a significant reduction in MACE in patients with type 2 diabetes and a recent acute coronary syndrome.- Therefore, it is not considered to be cardioprotective in the same way as liraglutide.*Teduglutide*- **Teduglutide** (Gattex) is a GLP-2 analogue, not a GLP-1 analogue [1].- It is primarily used for the treatment of **short bowel syndrome** and does not have indications or known benefits for cardiovascular protection in diabetes.

Q: What is the first-line treatment for chronic orthostatic hypotension?

Fludrocortisone. ***Fludrocortisone*** - **Fludrocortisone** is a **mineralocorticoid** that increases **sodium and water retention**, thereby expanding blood volume and improving orthostatic hypotension. - It is often considered a **first-line pharmacological agent** for chronic orthostatic hypotension, alongside non-pharmacological measures. *Dopamine* - **Dopamine** is a **vasopressor** typically used in **acute hypotensive states** and shock due to its potent vasoconstrictive and inotropic effects. - It is not a first-line agent for **chronic orthostatic hypotension** and has a short half-life, making it impractical for long-term management. *Diuretics* - **Diuretics** work by **decreasing blood volume** through increased urine output, which would worsen rather than improve orthostatic hypotension. - They are contraindicated in conditions like **orthostatic hypotension** where increased blood volume is desired. *Calcium channel blockers* - **Calcium channel blockers** are primarily used to treat **hypertension** and certain **arrhythmias** by causing **vasodilation** and reducing cardiac contractility. - Their vasodilatory effects would **aggravate hypotension**, making them unsuitable for treating orthostatic hypotension.

Q: A mixed α1 blocker and 5-HT1A receptor agonist, used as an antihypertensive agent, is which of the following?

Urapidil. ***Urapidil*** - **Urapidil** acts as a **mixed α1-blocker** and has an additional effect as a **5-HT1A receptor agonist**, which contributes to its antihypertensive properties beyond direct vasodilation. - Its unique dual mechanism sets it apart from other alpha-blockers by also modulating serotonin pathways to reduce blood pressure. *Trimazosin* - **Trimazosin** is a **direct-acting peripheral vasodilator** primarily described as an **alpha-adrenergic blocker**, but it does not possess significant 5-HT1A receptor agonist activity. - It is an older antihypertensive medication not commonly used today, with a primary mechanism focused solely on alpha-blocking. *Tamsulosin* - **Tamsulosin** is a **selective α1A-adrenergic receptor antagonist**, specifically used to treat **benign prostatic hyperplasia (BPH)** symptoms by relaxing smooth muscle in the prostate and bladder neck. - It does not have significant 5-HT1A receptor agonist activity, and its primary use is not for general hypertension management. *Doxazosin* - **Doxazosin** is a **selective α1-adrenergic receptor antagonist** used to treat both **hypertension** and **benign prostatic hyperplasia (BPH)**. - While it effectively blocks alpha-1 receptors to lower blood pressure, it does not exert significant agonistic effects on 5-HT1A receptors.

Q: What is the role of Bosentan in the treatment of pulmonary arterial hypertension?

Endothelin receptor blocker. ***Endothelin receptor blocker***- Bosentan is an **endothelin receptor antagonist** that blocks the effects of endothelin-1, a potent vasoconstrictor and smooth muscle proliferator [1, 3].- By blocking **endothelin receptors**, Bosentan causes vasodilation and reduces pulmonary vascular remodeling in patients with pulmonary arterial hypertension (PAH) [1, 2, 3].*ACEI*- **Angiotensin-converting enzyme inhibitors (ACEIs)** primarily act on the **renin-angiotensin-aldosterone system** to lower blood pressure in systemic hypertension and heart failure.- They are **not indicated for the treatment of pulmonary arterial hypertension** as their mechanism of action does not directly target the primary pathophysiology of PAH.*IIb/IIIa receptor blocker*- **Glycoprotein IIb/IIIa receptor blockers** are potent antiplatelet agents used in acute coronary syndromes and percutaneous coronary interventions to prevent **thrombosis**.- These agents specifically interfere with platelet aggregation and have **no role in the management of pulmonary arterial hypertension**.*Calcium channel blocker*- **Calcium channel blockers (CCBs)** are used in a small subset of PAH patients who demonstrate vasoreactivity on acute testing.- However, Bosentan is **not a calcium channel blocker**; it works through endothelin receptor antagonism, which is a completely different mechanism of action.

Q: Drug used for both the acute angina attack and prophylaxis of angina:

Isosorbide dinitrate. ***Isosorbide dinitrate***- This drug is a **nitrate** available in multiple formulations that can be used for **both acute relief and prophylaxis of angina** [1].- **Sublingual isosorbide dinitrate** has a rapid onset (2-5 minutes) making it suitable for **acute angina attacks**, while **oral formulations** provide longer duration of action for **prophylactic management** [1].- It works by causing **vasodilation**, primarily of veins, reducing **preload** and myocardial oxygen demand, and also dilates coronary arteries.- This dual-use capability through different formulations makes it unique among the given options.*Diltiazem*- Diltiazem is a **calcium channel blocker** primarily used for the **prophylaxis of angina** by reducing heart rate and myocardial contractility [2].- While effective for prevention, its onset of action is **too slow for acute angina relief**.*Verapamil*- Verapamil, another **calcium channel blocker**, is also used for **angina prophylaxis** due to its effects on reducing heart rate and contractility.- Similar to diltiazem, it is **not suitable for acute angina attacks** because it does not provide rapid relief.*Dipyridamole*- Dipyridamole is a **vasodilator** and a **platelet aggregation inhibitor**, primarily used in the prevention of thromboembolic events or as a pharmacologic stress agent.- Although it causes vasodilation, it is **not recommended for acute angina relief** or as a primary prophylactic agent for angina due to the risk of **coronary steal phenomenon** in some patients.

Q: Which medication is a selective beta-1 adrenergic blocker commonly used as a first-line treatment for hypertension?

Atenolol. ***Atenolol*** - **Atenolol** is a **selective beta-1 adrenergic blocker** [2], [4] that primarily blocks beta-1 receptors in the heart, reducing heart rate and contractility [3]. - Its **cardioselectivity** makes it a preferred first-line treatment for hypertension [1] due to fewer peripheral side effects compared to non-selective beta-blockers [3]. *Nor adrenaline* - **Noradrenaline** (norepinephrine) is a **sympathomimetic catecholamine** that primarily acts on alpha-1 and beta-1 adrenergic receptors, causing vasoconstriction and increased heart rate. - It is used in conditions like **septic shock** to raise blood pressure, not to treat chronic hypertension. *Dopamine* - **Dopamine** is a **catecholamine** with dose-dependent effects; low doses stimulate D1 receptors causing renal vasodilation, while higher doses stimulate beta-1 and alpha-1 receptors. - Its primary use is to treat **shock** and improve renal perfusion, not as a first-line antihypertensive. *Epinephrine* - **Epinephrine** (adrenaline) is a potent **vasoconstrictor** and **bronchodilator** that acts on alpha and beta adrenergic receptors, increasing heart rate, contractility, and blood pressure. - It is primarily used in **anaphylaxis** and cardiac arrest, not for chronic management of hypertension.

Q: Which of the following drugs is most classically associated with the coronary steal phenomenon?

Dipyridamole. ***Dipyridamole*** - **Dipyridamole** is a potent vasodilator that preferentially dilates healthy coronary arteries, diverting blood flow away from stenosed, ischemic areas. - This shunting of blood, known as the **coronary steal phenomenon**, can worsen ischemia in patients with coronary artery disease and is the basis of its use in cardiac stress testing. *Nitrates* - **Nitrates** primarily cause venodilation, reducing preload and myocardial oxygen demand, while also promoting epicardial coronary vasodilation. - While they can redistribute blood flow, they are generally used to treat angina and are not classically associated with the worsening of ischemia through a typical "steal" mechanism in the same way as dipyridamole. *Nifedipine* - **Nifedipine** is a dihydropyridine calcium channel blocker that causes peripheral and coronary vasodilation. - While it can lower blood pressure and improve coronary blood flow, it is not primarily associated with the **coronary steal phenomenon**; in fact, it can be used to treat myocardial ischemia. *Nicorandil* - **Nicorandil** is a potassium channel opener with nitrate-like properties, causing both arterial and venous dilation. - It works by reducing preload and afterload and directly dilating coronary arteries, making it beneficial for angina, rather than causing a coronary steal phenomenon.

Q: A 55-year-old patient with dyslipidemia and elevated LDL cholesterol is at increased risk of ischemic stroke. Which of the following is the most appropriate treatment to lower LDL cholesterol and reduce stroke risk?

Statins (HMG-CoA reductase inhibitors). ***Statins (HMG-CoA reductase inhibitors)*** - **Statins** are the first-line therapy for **dyslipidemia** due to their significant efficacy in lowering **LDL cholesterol** and their proven benefit in reducing the risk of **cardiovascular events**, including **ischemic stroke**. - They work by inhibiting **HMG-CoA reductase**, a key enzyme in **cholesterol synthesis** in the liver, which leads to increased **LDL receptor** expression and uptake of **LDL from the blood**. *Fibric acid derivatives* - **Fibric acid derivatives** (fibrates) primarily lower **triglycerides** and can modestly increase **HDL cholesterol**, but their effect on **LDL cholesterol** reduction is less pronounced than statins. - While they may reduce overall cardiovascular risk, they are not as effective as statins for primary **LDL-C lowering** and **stroke prevention** in patients with high LDL. *Nicotinic acid (niacin)* - **Niacin** can lower **LDL cholesterol**, triglycerides, and significantly increase **HDL cholesterol**; however, its use is limited by common side effects such as **flushing** and **pruritus**. - Clinical trials have not consistently shown that niacin provides additional cardiovascular benefit when added to statin therapy, and its primary role is not for aggressive **LDL-C reduction** in patients at high stroke risk. *Bile acid sequestrants* - **Bile acid sequestrants** (resins) lower **LDL cholesterol** by binding to bile acids in the intestine, preventing their reabsorption and promoting their excretion, which forces the liver to use more cholesterol to make new bile acids. - They are less potent than statins in lowering **LDL-C**, often cause gastrointestinal side effects like **constipation** and **bloating**, and are generally considered second-line or adjunctive therapy for **LDL reduction**.

Q: For a patient diagnosed with dyslipidemia characterized by elevated LDL cholesterol levels, what is the most appropriate treatment?

Statins. ***Statins*** - **Statins** are the frontline treatment for elevated **LDL cholesterol**, significantly reducing **cardiovascular risk** by inhibiting HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis. - They effectively **lower LDL levels** and have additional **pleiotropic effects** such as anti-inflammatory properties and plaque stabilization. *Fibric acid derivatives* - **Fibric acid derivatives** are primarily used to treat **hypertriglyceridemia** and can moderately increase HDL cholesterol, but they are less effective at lowering LDL cholesterol compared to statins. - They act by activating **PPAR-alpha**, leading to increased fatty acid oxidation and reduced triglyceride synthesis. *Nicotinic acid* - **Nicotinic acid** (niacin) is effective in **lowering triglycerides** and raising **HDL cholesterol**, but its impact on LDL cholesterol is less pronounced than statins, and it is associated with significant side effects like flushing. - It works by inhibiting hepatic VLDL synthesis and secretion, which indirectly impacts LDL formation. *Bile acid-binding resins* - **Bile acid-binding resins** reduce LDL cholesterol by binding bile acids in the intestine, leading to increased hepatic synthesis of bile acids from cholesterol and upregulation of LDL receptors. - While effective, they are generally less potent than statins and often cause **gastrointestinal side effects** such as constipation and bloating.

Q: Which of the following drugs acts as a direct vasodilator on blood vessels?

Hydralazine. ***Hydralazine*** - **Hydralazine** is a **direct-acting vasodilator** that works by directly relaxing the smooth muscle of **arterioles**. - Unlike drugs that work through receptors or central mechanisms, hydralazine acts **directly on vascular smooth muscle** to cause relaxation. - This direct relaxation leads to a decrease in **peripheral vascular resistance**, which lowers blood pressure. - It is a prototype drug for understanding direct vasodilator mechanisms. *Verapamil* - **Verapamil** is a **non-dihydropyridine calcium channel blocker** that works by blocking L-type calcium channels. - Its vasodilatory effects are **indirect**, mediated through calcium channel blockade rather than direct smooth muscle relaxation. - Its main actions are to reduce **heart rate** and **myocardial contractility**, with secondary vasodilation. *Propranolol* - **Propranolol** is a **non-selective beta-blocker** that primarily reduces blood pressure by decreasing heart rate and myocardial contractility. - Its effects on blood vessels are **indirect**, mainly by blocking **beta-1 receptors** in the heart and **beta-2 receptors** in the vasculature. - It is not a direct vasodilator and may even cause vasoconstriction due to unopposed alpha-adrenergic effects. *Methyldopa* - **Methyldopa** is an **alpha-2 adrenergic agonist** that acts **centrally** in the brainstem to reduce sympathetic outflow. - It does not directly act on blood vessels but rather reduces peripheral vascular tone through its **central nervous system effects**. - Its mechanism is indirect, working through the CNS rather than peripheral vascular tissue.

Question 1

Which of the following GLP-1 analogues is cardioprotective?

Accepted Answer

Liraglutide

Answer

Exenatide

Answer

Lixisenatide

Answer

Teduglutide

Question 2

What is the first-line treatment for chronic orthostatic hypotension?

Accepted Answer

Fludrocortisone

Answer

Dopamine

Answer

Diuretics

Answer

Calcium channel blockers

Question 3

A mixed α1 blocker and 5-HT1A receptor agonist, used as an antihypertensive agent, is which of the following?

Accepted Answer

Urapidil

Answer

Trimazosin

Answer

Tamsulosin

Answer

Doxazosin

Question 4

What is the role of Bosentan in the treatment of pulmonary arterial hypertension?

Accepted Answer

Endothelin receptor blocker

Answer

ACEI

Answer

IIb/IIIa receptor blocker

Answer

Calcium channel blocker

Question 5

Drug used for both the acute angina attack and prophylaxis of angina:

Accepted Answer

Isosorbide dinitrate

Answer

Diltiazem

Answer

Verapamil

Answer

Dipyridamole

Question 6

Which medication is a selective beta-1 adrenergic blocker commonly used as a first-line treatment for hypertension?

Accepted Answer

Atenolol

Answer

Noradrenaline

Answer

Dopamine

Answer

Epinephrine

Question 7

Which of the following drugs is most classically associated with the coronary steal phenomenon?

Accepted Answer

Dipyridamole

Answer

Nitrates

Answer

Nicorandil

Answer

Nifedipine

Question 8

A 55-year-old patient with dyslipidemia and elevated LDL cholesterol is at increased risk of ischemic stroke. Which of the following is the most appropriate treatment to lower LDL cholesterol and reduce stroke risk?

Accepted Answer

Statins (HMG-CoA reductase inhibitors)

Answer

Nicotinic acid (niacin)

Answer

Bile acid sequestrants

Answer

Fibric acid derivatives

Question 9

For a patient diagnosed with dyslipidemia characterized by elevated LDL cholesterol levels, what is the most appropriate treatment?

Accepted Answer

Statins

Answer

Fibric acid derivatives

Answer

Nicotinic acid

Answer

Bile acid-binding resins

Question 10

Which of the following drugs acts as a direct vasodilator on blood vessels?

Accepted Answer

Hydralazine

Answer

Verapamil

Answer

Propranolol

Answer

Methyldopa

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?